CSPI Calls on House to Fix FDA Reform Bill by Eliminating Conflict-of-Interest Waivers

Statement of CSPI Integrity in Science Director Merrill Goozner

May 9, 2007

It is disappointing that with a tie vote today, the Senate did not move toward ending the discredited practice of letting scientists with financial conflicts of interest serve on FDA advisory panels. Permitting experts with financial ties to drug companies to vote in FDA advisory committee meetings can have serious public health consequences.

Were grateful for the leadership of Senators Richard Durbin, Jeff Bingaman, and Barack Obama in offering their amendment today. There is clearly bipartisan support for limiting, if not ending altogether, the FDAs ability to waive conflict-of-interest rules. And we hope that when the House takes up the FDA reform bill, it will close the door that the Senate has left wide open.

We dont need another Vioxx.


Get Updates Via Email

Journalists can receive CSPI news releases via email.
Not a journalist?

Sign Up for Email Now



Subscribe Now

Subscribe Now »

Subscribe Today and Save!

In Recent Issues

Cover Story: What's the Catch? Why the Latest Study is Rarely the Final Answer

Special Feature: Fountain of Youth?

Brand-Name Rating: No-Prep Poultry

Subscribe Now

Request permission to reuse content

The use of information from this site for commercial purposes is strictly prohibited without written permission from CSPI.